which comes either as an auto-injector or as a pre-filled syringe. Indications for which Humira’s regulatory exclusivity have already lapsed include rheumatoid arthritis, Crohn’s disease ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...